SCHEMBL20889287

SCHEMBL20889287

Oc1ccc(-c2nc3ccccn3c2NC2CC2)c(O)c1O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SALL4 Q9UJQ4 4/20 0.65
ALDH1A1 P00352 5/20 0.53
GAA P10253 4/20 0.53
MAPT P10636 3/20 0.53
MAPK1 P28482 2/20 0.53
NPSR1 Q6W5P4 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
ADORA1 P30542 1/20 0.52
KDM4E B2RXH2 4/20 0.51
GFER P55789 2/20 0.51
ALOX5 P09917 2/20 0.51
TRIM33 Q9UPN9 3/20 0.49
HTT P42858 2/20 0.48
TRIM24 O15164 2/20 0.48
MEN1 O00255 1/20 0.48
LMNA P02545 1/20 0.48
TP53 P04637 1/20 0.48
ALOX15 P16050 1/20 0.48
TSHR P16473 1/20 0.48
CASP1 P29466 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20889569 0.94 SALL4 (0.67) SALL4ALDH1A1GAAMAPTMAPK1
SCHEMBL20889747 0.84 GAA (0.67) SALL4ALDH1A1GAAMAPTMAPK1
SCHEMBL2986458 0.81 ALOX5 (0.70) SALL4ALDH1A1GAAMAPTMAPK1
SCHEMBL1965729 0.81 ALOX5 (0.72) SALL4ALDH1A1GAAMAPTMAPK1
SCHEMBL2611922 0.80 SALL4 (0.64) SALL4ALDH1A1GAAMAPTMAPK1
SCHEMBL20889510 0.79 GAA (0.74) SALL4ALDH1A1GAAMAPTMAPK1
SCHEMBL20889790 0.79 SALL4 (0.64) SALL4ALDH1A1MAPTTRIM33TRIM24
SCHEMBL20889286 0.79 SALL4 (1.00) SALL4ALDH1A1GAAMAPTMAPK1
SCHEMBL2611941 0.78 ADORA1 (0.71) SALL4ALDH1A1GAAMAPTMAPK1
SCHEMBL20889787 0.77 SALL4 (0.65) SALL4ALDH1A1GAAMAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11530209-B2 Small molecule inhibition of transcription factor SALL4 and uses thereof DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-12-20 US disclosed
US-20200317664-A1 SMALL MOLECULE INHIBITION OF TRANSCRIPTION FACTOR SALL4 AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2020-10-08 US disclosed
WO-2019070943-A1 SMALL MOLECULE INHIBITION OF TRANSCRIPTION FACTOR SALL4 AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2019-04-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11530209-B2 Small molecule inhibition of transcription factor SALL4 and uses thereof SALL4, GLI2, TCF4 SALL4 1/4885ALDH1A1 1038/4885GAA 3761/4885
US-20200317664-A1 SMALL MOLECULE INHIBITION OF TRANSCRIPTION FACTOR SALL4 AND USES THEREOF SALL4, GLI2, TCF4 SALL4 1/4885ALDH1A1 1038/4885GAA 3761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.